Literature DB >> 28255112

[Salidroside improves pulmonary fibrosis by down-regulation of cathepsin B and NF-κBp65 in rats].

Xingren Liu1, Yifeng Bai2, Liang Liang2, Jing Feng3, Fei Deng4.   

Abstract

OBJECTIVE: To investigate the mechanism of salidroside in improvement of pulmonary fibrosis in rats.

Methods: SD rats were subjected to 6 groups: a blank group, a model group, a pirfenidone group, a high-dose salidroside group, a middle-dose salidroside group, and a low-dose salidroside group. The contents of ALB, ALP, LDH, PC-III and COL4, and the expression levels of cathepsin B (CB) and NF-κBp65 in the 6 groups were analyzed.

Results: Lung coefficient and oxygen partial pressure in the blank group were lower than those in the model group (P<0.05). Compared with the model group, lung coefficients in the pirfenidone group, the high-dose salidroside group, the middle-dose salidroside group, and the low-dose salidroside group were decreased, while oxygen partial pressures were statistically increased (P<0.05). The contents of ALB, ALP and LDH in the model group were statistically increased (P<0.05) in a dose-dependent manner. Compared with the blank group, the contents of GSH, HYP, PC-III and COL4, and the expression levels of CB and NF-κBp65 in the model group were significantly increased (P<0.05), which were attenuated by alidroside in a dose-dependent manner (P<0.05).

Conclusion: Salidroside can improve pulmonary fibrosis in rats, and the mechanism may be related to reduce the expression of CB and NF-κBp65.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28255112     DOI: 10.11817/j.issn.1672-7347.2017.02.002

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  1 in total

1.  Salidroside protects PC-12 cells against amyloid β-induced apoptosis by activation of the ERK1/2 and AKT signaling pathways.

Authors:  Zheng-Luan Liao; Heng Su; Yun-Fei Tan; Ya-Ju Qiu; Jun-Peng Zhu; Yan Chen; Si-Si Lin; Ming-Hao Wu; Yan-Ping Mao; Jiao-Jiao Hu; En-Yan Yu
Journal:  Int J Mol Med       Date:  2019-02-01       Impact factor: 4.101

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.